DSM fails to sell Special Products to Arsenal
Global life sciences and materials sciences company DSM will not sell its Special Products division to US-based Arsenal Capital Partners due to provisions imposed by the European Commission. The deal was originally announced on 3 March 2008.
In August 2008, the European Commission announced an in-depth investigation into the transaction.
Last month, the European Commission approved the sale, but the conditions the Commission demanded have led to the conclusion that the intended sale is no longer feasible.
DSM will continue the divestment process for DSM Special Products, as part of its Vision 2010 strategy.
DSM Special Products is the producer of Purox®, an ingredient used in food as well as in a range of industrial applications. It also produces an ingredient for VevoVitall®, a product for the animal health market that will remain with DSM Nutritional Products.
DSM Special Products employs around 130 people in Rotterdam and Sittard (Netherlands), and has an annual turnover of approximately EUR 100 million.
To comment, register here
Or register to be able to comment.